Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00176579
Status:
COMPLETED
Last Update Posted:
2011-08-12
First Post:
2005-09-13
Brief Title:
Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer
Sponsor:
University of Medicine and Dentistry of New Jersey
Organization:
Rutgers The State University of New Jersey
Study Overview
Official Title:
Assessing Bone Mineral Density as a Risk Factor for Early Clinically Significant Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Measuring bone mineral density may help doctors predict whether prostate cancer will come back It may also help the study of prostate cancer in the future
PURPOSE This clinical trial is studying whether bone mineral density affects cancer recurrence in patients with early stage prostate cancer
PURPOSE This clinical trial is studying whether bone mineral density affects cancer recurrence in patients with early stage prostate cancer
Detailed Description:
OBJECTIVES
Determine bone mineral density BMD in patients with clinically significant early stage prostate cancer
Determine whether patients who have a higher level of BMD and have had a radical prostatectomy for cure are less likely to have an early relapse ie less than 3 years than those patients with a low level of BMD
OUTLINE This is a case-controlled study followed by a prospective longitudinal cohort study
Patients undergo bone mineral density BMD measurements by dual-energy x-ray absorptiometry with a densitometer Posteroanterior measurements of the total hip are also recorded
Patients also undergo blood collection to examine markers that provide evidence of systemic disease
Patients are followed every 6 months for 3 years
PROJECTED ACCRUAL A total of 40 patients will be accrued for this study
Determine bone mineral density BMD in patients with clinically significant early stage prostate cancer
Determine whether patients who have a higher level of BMD and have had a radical prostatectomy for cure are less likely to have an early relapse ie less than 3 years than those patients with a low level of BMD
OUTLINE This is a case-controlled study followed by a prospective longitudinal cohort study
Patients undergo bone mineral density BMD measurements by dual-energy x-ray absorptiometry with a densitometer Posteroanterior measurements of the total hip are also recorded
Patients also undergo blood collection to examine markers that provide evidence of systemic disease
Patients are followed every 6 months for 3 years
PROJECTED ACCRUAL A total of 40 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CINJ-4375 | US NIH GrantContract | None | httpsreporternihgovquickSearchP30CA072720 |
| P30CA072720 | NIH | None | None |
| CINJ-5004 | None | None | None |